查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1683388

全球奈米技術藥物傳輸設備市場 - 2025 至 2033 年

Global Nanotechnology-Enabled Drug Delivery Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球奈米技術藥物輸送設備市場規模達到 542.2 億美元，預計到 2033 年將達到 1,791.2 億美元，在 2025-2033 年預測期內的複合年成長率為 12.6%。

奈米技術的藥物傳輸裝置是利用奈米技術提高治療劑的功效、精確度和安全性的先進系統。這些裝置使用奈米粒子、脂質體、樹枝狀聚合物和聚合物膠束等奈米級材料來增強藥物溶解度、生物利用度和向特定組織或細胞的靶向傳遞。這些系統最大限度地減少了副作用，增強了治療效果，並實現了個人化的治療方法，特別是在腫瘤學、神經病學和傳染病治療方面。

市場動態：

促進因素與約束因素

提高藥物生物利用度和標靶輸送

由於奈米技術能夠提高藥物生物利用度和標靶輸送，全球藥物輸送裝置市場正在不斷擴大。這些系統透過將藥物輸送到特定組織或患病細胞來增強治療效果，並最大限度地減少副作用。它們在腫瘤學、神經病學和心血管疾病中特別有用，因為它們可以提高溶解度、延長循環時間並允許控制藥物釋放。這些創新也促進了藥物跨越生物屏障的運輸，這對於治療複雜疾病至關重要。

可擴展性和製造複雜性有限

全球奈米技術藥物傳輸設備市場面臨重大挑戰，因為大規模製造的複雜性，包括精密工程、專門設施和嚴格的品質控制措施。奈米顆粒尺寸、穩定性和藥物負載效率的變化會影響產品的一致性，進而導致監管受挫。維護先進製造基礎設施和確保批次間一致性的高成本進一步限制了市場擴張，限制了奈米技術在藥物傳輸中的廣泛應用。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 提高藥物生物利用度和標靶輸送
      • 奈米科技的進步
    • 限制
      • 可擴展性和製造複雜性有限
      • 開發和製造成本高
    • 機會
      • 與人工智慧和智慧藥物傳輸系統的整合
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：依產品類型

  • 奈米晶體
  • 奈米粒子
  • 脂質體
  • 膠束
  • 奈米管
  • 其他

第 6 章：按應用

  • 神經病學
  • 腫瘤學
  • 心血管/生理學
  • 抗發炎/免疫學
  • 抗感染
  • 其他

第 7 章：按最終用戶

  • 醫院和診所
  • 研究機構和實驗室
  • 製藥和生物技術公司
  • 其他

第 8 章：按區域市場分析與成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Merck & Co., Inc
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • Gilead Sciences, Inc.
  • GSK

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD9330

The global nanotechnology-enabled drug delivery devices market reached US$ 54.22 billion in 2024 and is expected to reach US$ 179.12 billion by 2033, growing at a CAGR of 12.6% during the forecast period 2025-2033.

Nanotechnology-enabled drug delivery devices are advanced systems that use nanotechnology to improve the efficacy, precision, and safety of therapeutic agents. These devices use nanoscale materials like nanoparticles, liposomes, dendrimers, and polymeric micelles to enhance drug solubility, bioavailability, and targeted delivery to specific tissues or cells. These systems minimize side effects, enhance therapeutic outcomes, and enable personalized treatment approaches, particularly in oncology, neurology, and infectious disease treatments.

Market Dynamics: Drivers & Restraints

Enhanced Drug Bioavailability and Targeted Delivery

The global market for nanotechnology-enabled drug delivery devices is expanding due to its ability to improve drug bioavailability and targeted delivery. These systems enhance therapeutic effectiveness by delivering drugs to specific tissues or diseased cells, minimizing side effects. They are particularly useful in oncology, neurology, and cardiovascular diseases, as they improve solubility, prolong circulation time, and allow controlled drug release. These innovations also facilitate drug transport across biological barriers, making them crucial for treating complex conditions.

Limited Scalability and Manufacturing Complexities

The global nanotechnology-enabled drug delivery devices market faces significant challenges due to the complexities of large-scale manufacturing, including precise engineering, specialized facilities, and strict quality control measures. Variability in nanoparticle size, stability, and drug-loading efficiency can impact product consistency, leading to regulatory setbacks. High costs associated with maintaining advanced manufacturing infrastructure and ensuring batch-to-batch uniformity further restrict market expansion, limiting the widespread adoption of nanotechnology in drug delivery.

Segment Analysis

The global nanotechnology-enabled drug delivery devices market is segmented based on product type, application, end-user and region.

Product Type:

The nanocrystals from product type segment is expected to dominate the nanotechnology-enabled drug delivery devices market with the highest market share

Nanocrystals are a key component in the global drug delivery device market, enhancing the solubility and bioavailability of water-soluble drugs. These ultra-small particles improve drug dissolution rates, leading to faster absorption and increased therapeutic efficacy. They enable controlled, targeted drug release, reducing dosage frequency and side effects. Their applications are particularly significant in oncology, neurology, and cardiovascular treatments. Nanocrystals can be administered via oral, injectable, and topical formulations, expanding their potential across multiple therapeutic areas.

Geographical Analysis

North America is expected to hold a significant position in the Nanotechnology-Enabled Drug Delivery Devices market with the highest market share

North America dominates the global nanotechnology-enabled drug delivery devices market due to strong research, a well-established pharmaceutical industry, and advanced healthcare infrastructure. Major pharmaceutical and biotechnology companies invest in nanotechnology-based solutions. The rising prevalence of chronic diseases like cancer, neurological disorders, and cardiovascular conditions drives demand for innovative drug delivery systems. Collaborations between research institutions and pharmaceutical companies drive innovation, positioning North America as a dominant player.

For instance, according to the Centers for Disease Control and Prevention 6 in 10 Americans have at least one chronic disease, with 4 in 10 having two or more. Preventable chronic diseases are often caused by risky behaviors like smoking, poor nutrition, physical inactivity, and excessive alcohol use.

Hence, North America's increasing chronic disease prevalence drives demand for advanced drug delivery solutions, promoting nanotechnology-enabled devices for treatment efficiency, side effects reduction, and improved patient compliance, boosting market growth.

Competitive Landscape

The major global players in the nanotechnology-enabled drug delivery devices market include Merck & Co., Inc, Pfizer Inc, Novartis AG, Sanofi S.A., Gilead Sciences, Inc, and GSK among others.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nanotechnology-enabled drug delivery devices market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Enhanced Drug Bioavailability and Targeted Delivery
      • 3.1.1.2. Advancements in Nanotechnology
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Scalability and Manufacturing Complexities
      • 3.1.2.2. High Development and Manufacturing Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with AI and Smart Drug Delivery Systems
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Nanocrystals*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Nanoparticles
  • 5.4. Liposomes
  • 5.5. Micelles
  • 5.6. Nanotubes
  • 5.7. Others

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Neurology*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Oncology
  • 6.4. Cardiovascular/Physiology
  • 6.5. Anti-inflammatory/Immunology
  • 6.6. Anti-infective
  • 6.7. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals and Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Research Institutes and Laboratories
  • 7.4. Pharmaceutical and Biotechnology Companies
  • 7.5. Others

8. By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Pfizer Inc.
  • 10.3. Novartis AG
  • 10.4. Sanofi S.A.
  • 10.5. Gilead Sciences, Inc.
  • 10.6. GSK

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us